

Resolution n°1-2021-e

Additional contributions from Canada and Norway

Noting the following offers of additional contributions to Unitaid:

- CAD 15 million (fifteen million Canadian dollars) from Canada to support Unitaid's efforts in ACT-A Therapeutics pillar; and
- NOK 350 million (three hundred and fifty million Norwegian kroner) from Norway to support Unitaid's efforts in ACT-A Therapeutics and Diagnostics pillars; and

Acknowledging the revised guiding principles and criteria for additional contributions presented at the 20th meeting of the Policy and Strategy Committee (UNITAID/PSC20/2018/4/REV1), the Executive Board is satisfied that the additional funding proposed by Canada and Norway is aligned with the guiding principles and meets the criteria therein.

Accordingly, the Executive Board welcomes the offers of additional funding from Canada and Norway and instructs the Secretariat to undertake any necessary administrative arrangements to accept them.

These additional contributions are subject to overhead recovery charges (ORC) of 2% as defined by the Executive Board during its 37th Session. ORC charged with respect to these additional contributions shall be attributed to Unitaid's 2021 Board-approved operating costs, to offset the ACTA 2021 supplemental budget of US\$ 2.25 million. The ORC is included in the amounts mentioned above and is not additional to the amounts being contributed.

The Executive Board acknowledges that Norway's additional contribution will be provided on the basis that NOK 100 million (one hundred million Norwegian kroner) is to be disbursed by Unitaid to the Foundation for Innovative New Diagnostics (FIND) for activities supporting the Unitaid-Board approved Covid-19 Investment Case in diagnostics. The Board therefore authorizes Unitaid's Executive Director to disburse this amount, net of Unitaid's applicable ORC, subject to Unitaid's receipt of the full amount of the additional contribution from Norway and the signature of a legal agreement with FIND reflecting these arrangements.

hanisel Tumer w

Marisol Touraine
Chair of the Unitaid Executive Board

Date: 28 January 2021